Present and future drug treatment for Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Present and future drug treatment for Parkinson's disease.

Present and future drug treatment for Parkinson's disease.

http://www.wikidata.org/entity/Q35484805

about

Parkinson's disease: from monogenic forms to genetic susceptibility factors Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1 Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.Noradrenaline and Parkinson's disease.HIV-1 proteins, Tat and gp120, target the developing dopamine system Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?A perspective on the current issues in the diagnosis of Parkinson's disease.Death in the substantia nigra: a motor tragedy.Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders Slowly progressive dopamine cell loss--a model on which to test neuroprotective strategies for Parkinson's disease?Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.Levodopa delivery systems: advancements in delivery of the gold standard.Oxidative stress in genetic mouse models of Parkinson's disease.Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases.Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease.Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors.Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A2A antagonists/MAO‑B inhibitors.Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of parkinson's disease

P2860

Q22242870-E6263970-90F7-4E62-81D3-5950E34A56A7 Q24647141-BC6AA9E3-B333-4A74-8CF9-590BEA8C784D Q26747508-978E0448-AC0B-439D-A68C-2F79E9EF699B Q28542729-BD0A5390-730F-4641-9FBA-8D47B40F5D59 Q28591830-B781C15C-BFC1-48BA-BA19-81CC6127AF6E Q34619534-284EBC4F-800F-4C63-8980-068AEFF1A1A0 Q35013240-E33A4C70-1116-427B-94D6-784F3D7A261B Q35743630-12AFB04E-91CD-46F8-88F9-EC8F053073A2 Q36499640-426732CD-20AF-4E91-A626-6F07B2911211 Q36842617-4CB27D0D-63DF-4C3C-8C19-F629ACEE1696 Q36847262-FF85AD3E-6D74-4626-BA91-524159B4D592 Q37249765-A122B5D3-7893-47C1-A955-0F794BCE6257 Q37602127-D7A6AA24-96E0-4F45-8C76-F337F3D01DD9 Q37644437-DFAFBCB3-782D-485C-876E-C3F1438CA370 Q37679951-3A1EA8DA-2A3D-4F6B-85C7-FEF6CC26A966 Q38029327-9E396E96-F7CF-45BE-94C6-F3CD78266A8E Q38764212-B5983FD4-DDBF-462B-9DE7-5B035FAE4B6F Q42501960-C3F07B46-9BEA-47D3-BFA2-F407CB950A17 Q42856693-481B9AB8-9EA5-4ED2-A910-CFD25E5AD4A6 Q43182160-517908C1-4BD4-420B-88BE-CF4D2C082A1C Q48395382-8D1F57AD-33F1-4640-8DCA-5DD7D506C1D7 Q50880865-463760F2-CE67-4085-B120-E01B2DBFB019 Q57369531-F86609C5-15F2-41AB-8A8F-73F1EBF0B19B

P2860

Present and future drug treatment for Parkinson's disease.

http://www.wikidata.org/entity/Q35484805

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Present and future drug treatment for Parkinson's disease.

@ast

Present and future drug treatment for Parkinson's disease.

@en

type

label

Present and future drug treatment for Parkinson's disease.

@ast

Present and future drug treatment for Parkinson's disease.

@en

prefLabel

Present and future drug treatment for Parkinson's disease.

@ast

Present and future drug treatment for Parkinson's disease.

@en

P1433

Q35484805-767A4015-BEF8-4FA9-BE2C-5155B2170177

P1476

Q35484805-364F11C5-7FBF-46DA-BCEB-60D2FEB9EECB

P2093

Q35484805-E90C35C3-A159-4B73-B1C1-27EC74A02EE0

P2860

Q35484805-0A83DC5A-737C-475F-B4E9-2F35F4C4CEED

Q35484805-0B78E6FA-8C53-4F4C-AE8C-D744DD45676E

Q35484805-0D6FFB8B-F41C-4DC1-98AA-3C07663CD894

Q35484805-100EA248-0D63-45A0-9B31-0D46C1E6DEDF

Q35484805-118EA55C-8715-423D-9B7B-628A966435F1

Q35484805-11AC752B-4680-4017-97D8-EDAC53B7CC9B

Q35484805-11B05B48-89AC-490C-AEE4-B03E094C8071

Q35484805-11D671B6-32EF-43C4-A0D1-D7D64399AAB5

Q35484805-17DC9A02-0A10-4CFA-8DD4-C33C50DF004E

Q35484805-1ABDC1C4-5E81-401D-8E2D-D00290006943

P304

Q35484805-6767AE84-B5D4-4823-BE89-B8EB537A2336

P31

Q35484805-F6660EEA-1738-4099-96CF-B2576F856C4D

P356

Q35484805-0E55AB68-CB11-4BFB-83B1-CFCD750978C8

P407

Q35484805-E26C7498-3881-43DA-9610-022049203C13

P433

Q35484805-7DCF860A-1449-42CE-8746-9FEE9F5A15FC

P478

Q35484805-E738539B-6A62-4E3F-8E6C-3F35271B93F7

P577

Q35484805-4EB6F2F4-8576-4316-9810-8CE4F79BDCA7

P5875

Q35484805-D4E75801-05DA-4143-A573-D8BDA040A64D

P698

Q35484805-F73128AD-BA55-4F28-AC38-CAEB57890574

P921

Q35484805-8601B262-EAC2-47E8-9CB0-74667C4DB26F

P932

Q35484805-0BBFBA92-A5D5-4D5A-9E15-B9E756ED8BD8

P356

JNNP.2004.035980

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Present and future drug treatment for Parkinson's disease.

@en

P2093

Schapira AH

http://www.w3.org/2001/XMLSchema#string

P2860

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease

Amantadine in Parkinson's disease

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

Staging of brain pathology related to sporadic Parkinson's disease

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension

Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys

P304

1472-1478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.2004.035980

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7537950

http://www.w3.org/2001/XMLSchema#string

P698

16227533

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

1739397

http://www.w3.org/2001/XMLSchema#string